Research programme: cancer vaccine - Boehringer Ingelheim
Alternative Names: RNA vaccinesLatest Information Update: 28 Aug 2021
At a glance
- Originator Boehringer Ingelheim
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in USA